Standard InChI: InChI=1S/C24H34O5/c1-22-9-7-16(25)11-15(22)4-5-18-17(22)8-10-23(2)21(19(26)12-24(18,23)28)14-3-6-20(27)29-13-14/h3,6,13,15-19,21,25-26,28H,4-5,7-12H2,1-2H3/t15-,16+,17+,18-,19+,21+,22+,23-,24+/m1/s1
Standard InChI Key: MWFCMSURKYLINK-QDLCSJEJSA-N
Associated Targets(Human)
KB 17409 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
HL-60 67320 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
H(+)/Cl(-) exchange transporter 3 23 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
HepG2 196354 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Associated Targets(non-human)
MH60 82 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
CCRF S-180 1031 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
H22 575 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Molecule Features
Natural Product: Yes
Oral: No
Chemical Probe: No
Parenteral: No
Molecule Type: Small molecule
Topical: No
First In Class: No
Black Box: No
Chirality: No
Availability: No
Prodrug: No
Drug Indications
MESH ID
MESH Heading
EFO IDs
EFO Terms
Max Phase for Indication
References
Mechanisms of Action
Mechanism of Action
Action Type
target ID
Target Name
Target Type
Target Organism
Binding Site Name
References
Properties
Molecular Weight: 402.53
Molecular Weight (Monoisotopic): 402.2406
AlogP: 3.21
#Rotatable Bonds: 1
Polar Surface Area: 90.90
Molecular Species: NEUTRAL
HBA: 5
HBD: 3
#RO5 Violations: 0
HBA (Lipinski): 5
HBD (Lipinski): 3
#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.99
CX Basic pKa:
CX LogP: 1.90
CX LogD: 1.90
Aromatic Rings: 1
Heavy Atoms: 29
QED Weighted: 0.67
Np Likeness Score: 2.80
References
1.Kamano Y, Yamashita A, Nogawa T, Morita H, Takeya K, Itokawa H, Segawa T, Yukita A, Saito K, Katsuyama M, Pettit GR.. (2002) QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1)., 45 (25):[PMID:12459012][10.1021/jm0202066]
2.Nogawa T, Kamano Y, Yamashita A, Pettit GR.. (2001) Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su., 64 (9):[PMID:11575946][10.1021/np0101088]
3.Liu J, Zhang D, Li Y, Chen W, Ruan Z, Deng L, Wang L, Tian H, Yiu A, Fan C, Luo H, Liu S, Wang Y, Xiao G, Chen L, Ye W.. (2013) Discovery of bufadienolides as a novel class of ClC-3 chloride channel activators with antitumor activities., 56 (14):[PMID:23799775][10.1021/jm400881m]